2014 - Fellow of the American Association for the Advancement of Science (AAAS)
Jules L. Dienstag focuses on Internal medicine, Gastroenterology, Immunology, Hepatitis B virus and Hepatitis C. His study on Internal medicine is mostly dedicated to connecting different topics, such as Ribavirin. The concepts of his Gastroenterology study are interwoven with issues in Interferon and Surgery.
His Immunology and Hepatitis, Viral disease, Hepatitis C virus, Antibody and Human leukocyte antigen investigations all form part of his Immunology research activities. Hepatitis B virus is a subfield of Virology that Jules L. Dienstag explores. The Hepatitis C study combines topics in areas such as Pegylated interferon and Maintenance therapy.
His primary areas of investigation include Immunology, Internal medicine, Virology, Hepatitis and Gastroenterology. His work on Immunology deals in particular with Hepatitis B, Antibody, Hepatitis B virus, HBsAg and Viral disease. His Internal medicine research is multidisciplinary, incorporating elements of Ribavirin and Surgery.
His Virology research integrates issues from Serology and Antigen. The various areas that Jules L. Dienstag examines in his Hepatitis study include Chronic liver disease and Outbreak. His work carried out in the field of Gastroenterology brings together such families of science as Interferon, Liver transplantation, Liver biopsy and Pathology.
Jules L. Dienstag mostly deals with Internal medicine, Gastroenterology, Hepatitis C, Cirrhosis and Immunology. Many of his studies involve connections with topics such as Ribavirin and Internal medicine. His research on Gastroenterology also deals with topics like
His Hepatitis C study combines topics in areas such as Surgery, Fibrosis, Biopsy, Pathology and Hepatocellular carcinoma. In Cirrhosis, Jules L. Dienstag works on issues like Hepatitis C virus, which are connected to Viral load. As part of his studies on Immunology, Jules L. Dienstag frequently links adjacent subjects like Drug resistance.
His scientific interests lie mostly in Internal medicine, Hepatitis C, Cirrhosis, Gastroenterology and Hepatocellular carcinoma. The concepts of his Internal medicine study are interwoven with issues in Immunology and Oncology. His work deals with themes such as Randomized controlled trial and Pathology, which intersect with Hepatitis C.
His Cirrhosis study integrates concerns from other disciplines, such as Ribavirin, Hepatitis C virus, Maintenance therapy, Hepatitis and Hepatology. His Gastroenterology research incorporates elements of Viral hepatitis, Liver biopsy, Fibrosis and Surgery. Jules L. Dienstag works mostly in the field of Hepatitis B, limiting it down to concerns involving Adverse effect and, occasionally, Hepatitis B virus.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis
G. Kuo;Q.-L. Choo;H.J. Alter;G.L. Gitnick.
Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States
George Ostapowicz;Robert J. Fontana;Frank V. Schioødt;Anne Larson.
Annals of Internal Medicine (2002)
Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.
Davis Gl;Balart La;Schiff Er;Lindsay K.
The New England Journal of Medicine (1989)
Viral Hepatitis and Liver Disease
Girish N. Vyas;Jules Dienstag;Jay H. Hoofnagle.
Lamivudine as initial treatment for chronic hepatitis B in the United States.
Jules L. Dienstag;Eugene R. Schiff;Teresa L. Wright;Robert P. Perrillo.
The New England Journal of Medicine (1999)
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
John G. McHutchison;Michael Manns;Keyur Patel;Thierry Poynard.
A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection
Jules L. Dienstag;Robert P. Perrillo;Eugene R. Schiff;Maria Bartholomew.
The New England Journal of Medicine (1995)
Hepatitis B Virus Infection
Jules L. Dienstag.
The New England Journal of Medicine (2008)
Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
Anna S.F. Lok;Ching Lung Lai;Nancy Leung;Guang Bi Yao.
A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B
Robert P. Perrillo;Eugene R. Schiff;Gary L. Davis;Henry C. Bodenheimer.
The New England Journal of Medicine (1990)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: